Li Hao
Li Hao has a total of 157 co-authors. Here are the top co-authors by number of shared publications:
Annaliesa S. Anderson
Vaccines, Pfizer Inc, Pearl River, USA
7 shared publications- Annaliesa S. Anderson
Pfizer Vaccine Research and Development
5 shared publications Paul A. Liberator
Vaccines, Pfizer Inc, Pearl River, USA
5 shared publicationsJonathan T. Lee
Vaccines, Pfizer Inc, Pearl River, USA
4 shared publicationsLubomira Andrew
Vaccines, Pfizer Inc, Pearl River, USA
4 shared publications- Jonathan T. Lee
Vaccine Research and Development, Pfizer, Inc., Pearl River, NY, 10965, USA
3 shared publications
Latest Publications
- Open Access
- 23 March 2026
- Published by Microbiology Society in Microbial Genomics
- Vol. 12  (3) , 001666
Population genomic variation in Staphylococcus aureus isolates from carriage and disease in Indigenous communities in the Southwest United States
Indigenous populations in the USA experience disproportionately high rates of Staphylococcus aureus invasive disease, yet the drivers of this disparity remain unclear. To investigate the role of bacterial population structure, we conducted whole-genome sequencing of 589 invasive S. aureus isolates and 125 carriage isolates collected from the Navajo Nation and White Mountain Apache (N/WMA) tribal lands in the Southwest USA. We compared lineage distribution between invasive disease and carriage, and to a contemporaneous set of bloodstream isolates from New Hampshire (NH) ( n =377), using a Monte Carlo simulation based on the relative frequency ratio (RFR). Methicillin-resistant S. aureus accounted for 33.4% of invasive infections in N/WMA, and the most prevalent lineages were multi-locus sequence types (STs) 8 and 5. ST8 and ST97 were significantly enriched in invasive disease relative to carriage in N/WMA, suggesting increased invasiveness. Compared to NH, invasive disease in N/WMA was associated with higher frequencies of ST8, ST97 and ST188, while ST5 and ST30 were more common in NH. These findings highlight substantial geographic variation in S. aureus population structure and suggest that lineage composition may contribute to the elevated burden of invasive disease in Indigenous communities in the Southwest US. Our study underscores the importance of integrating genomic surveillance with epidemiologic data to inform prevention strategies.
- 23 March 2026
- Published by Microbiology Society in Microbial Genomics
- Vol. 12  (3) , 001666
Open AccessPopulation genomic variation in Staphylococcus aureus isolates from carriage and disease in Indigenous communities in the Southwest United States
Indigenous populations in the USA experience disproportionately high rates of Staphylococcus aureus invasive disease, yet the drivers of this disparity remain unclear. To investigate the role of bacterial population structure, we conducted whole-genome sequencing of 589 invasive S. aureus isolates and 125 carriage isolates collected from the Navajo Nation and White Mountain Apache (N/WMA) tribal lands in the Southwest USA. We compared lineage distribution between invasive disease and carriage, and to a contemporaneous set of bloodstream isolates from New Hampshire (NH) ( n =377), using a Monte Carlo simulation based on the relative frequency ratio (RFR). Methicillin-resistant S. aureus accounted for 33.4% of invasive infections in N/WMA, and the most prevalent lineages were multi-locus sequence types (STs) 8 and 5. ST8 and ST97 were significantly enriched in invasive disease relative to carriage in N/WMA, suggesting increased invasiveness. Compared to NH, invasive disease in N/WMA was associated with higher frequencies of ST8, ST97 and ST188, while ST5 and ST30 were more common in NH. These findings highlight substantial geographic variation in S. aureus population structure and suggest that lineage composition may contribute to the elevated burden of invasive disease in Indigenous communities in the Southwest US. Our study underscores the importance of integrating genomic surveillance with epidemiologic data to inform prevention strategies.
- Open Access
- 27 November 2025
- Published by Springer Nature in BMC Genomics
- Vol. 26  (1)
Genomic characterization of clinical Borrelia burgdorferi sensu lato isolates in the Netherlands over a thirty-year period
Background: Lyme borreliosis (LB), the most common vector-borne disease in the Northern Hemisphere, is caused by a multitude of pathogenic Borrelia burgdorferi sensu lato (sl) species endemic to northern, western, and central regions of Europe. We utilized whole genome sequencing (WGS) to characterize the genetic diversity of 130 clinical B. burgdorferi sl isolates collected from LB cases in the Netherlands between 1988 and 2023, the majority of which were B. afzelii . Results: WGS analysis revealed significant diversity, including 29 different multi-locus sequence types (MLSTs) across four genospecies. Plasmids from B. garinii and B. bavariensis were found to exhibit greater sequence diversity than those from B. burgdorferi sensu stricto and B. afzelii . We further characterized the Borrelia membrane protein antigens OspA, OspC and DbpA for sequence diversity and correlation with LB disease state. Conclusions: This large-scale genomic analysis of clinical Dutch B. burgdorferi sl isolates furthers our understanding of LB and may indicate potential coverage for LB vaccine candidates in clinical development.
- 27 November 2025
- Published by Springer Nature in BMC Genomics
- Vol. 26  (1)
Open AccessGenomic characterization of clinical Borrelia burgdorferi sensu lato isolates in the Netherlands over a thirty-year period
Background: Lyme borreliosis (LB), the most common vector-borne disease in the Northern Hemisphere, is caused by a multitude of pathogenic Borrelia burgdorferi sensu lato (sl) species endemic to northern, western, and central regions of Europe. We utilized whole genome sequencing (WGS) to characterize the genetic diversity of 130 clinical B. burgdorferi sl isolates collected from LB cases in the Netherlands between 1988 and 2023, the majority of which were B. afzelii . Results: WGS analysis revealed significant diversity, including 29 different multi-locus sequence types (MLSTs) across four genospecies. Plasmids from B. garinii and B. bavariensis were found to exhibit greater sequence diversity than those from B. burgdorferi sensu stricto and B. afzelii . We further characterized the Borrelia membrane protein antigens OspA, OspC and DbpA for sequence diversity and correlation with LB disease state. Conclusions: This large-scale genomic analysis of clinical Dutch B. burgdorferi sl isolates furthers our understanding of LB and may indicate potential coverage for LB vaccine candidates in clinical development.
- Open Access
- 10 October 2024
- Published by Taylor & Francis in Human Vaccines & Immunotherapeutics
- Vol. 20  (1) , 2409502
Factor H binding protein (FHbp): An evaluation of genotypic diversity across Neisseria meningitidis serogroups
Neisseria meningitidis serogroups A, B, C, W, X, and Y cause invasive meningococcal disease (IMD) worldwide. Factor H binding protein (FHbp), a key meningococcal virulence factor, is an antigen included in both licensed meningococcal serogroup B (MenB) vaccines. This review examines the biology and epidemiology of FHbp and assesses the ability and potential of FHbp vaccine antigens to protect against IMD. Using evidence from the literature and the contemporary PubMLST database, we discuss analyses of MenB genotypes on the representation of the most prevalent multilocus sequence typing (MLST)/clonal complexes, FHbp subfamily distribution, and FHbp and porin A (PorA) variants. We further discuss that the similar genotypes, distribution, and diversity of FHbp variant types have remained stable over long time periods, supporting the potential for FHbp-containing, protein-based vaccines to protect against IMD, including MenB-FHbp (Trumenba®), which contains two lipidated FHbp antigens (one each from both FHbp subfamilies: A and B).
- 10 October 2024
- Published by Taylor & Francis in Human Vaccines & Immunotherapeutics
- Vol. 20  (1) , 2409502
Open AccessFactor H binding protein (FHbp): An evaluation of genotypic diversity across Neisseria meningitidis serogroups
Neisseria meningitidis serogroups A, B, C, W, X, and Y cause invasive meningococcal disease (IMD) worldwide. Factor H binding protein (FHbp), a key meningococcal virulence factor, is an antigen included in both licensed meningococcal serogroup B (MenB) vaccines. This review examines the biology and epidemiology of FHbp and assesses the ability and potential of FHbp vaccine antigens to protect against IMD. Using evidence from the literature and the contemporary PubMLST database, we discuss analyses of MenB genotypes on the representation of the most prevalent multilocus sequence typing (MLST)/clonal complexes, FHbp subfamily distribution, and FHbp and porin A (PorA) variants. We further discuss that the similar genotypes, distribution, and diversity of FHbp variant types have remained stable over long time periods, supporting the potential for FHbp-containing, protein-based vaccines to protect against IMD, including MenB-FHbp (Trumenba®), which contains two lipidated FHbp antigens (one each from both FHbp subfamilies: A and B).
- Top Cited PapersOpen Access
- 30 August 2024
- Published by American Association for the Advancement of Science (AAAS) in Science Advances
- Vol. 10  (35) , eado4288
Discovery of SARS-CoV-2 papain-like protease (PL pro ) inhibitors with efficacy in a murine infection model
Vaccines and first-generation antiviral therapeutics have provided important protection against COVID-19 caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). However, there remains a need for additional therapeutic options that provide enhanced efficacy and protection against potential viral resistance. The SARS-CoV-2 papain-like protease (PL pro ) is one of the two essential cysteine proteases involved in viral replication. While inhibitors of the SARS-CoV-2 main protease have demonstrated clinical efficacy, known PL pro inhibitors have, to date, lacked the inhibitory potency and requisite pharmacokinetics to demonstrate that targeting PL pro translates to in vivo efficacy in a preclinical setting. Here, we report the machine learning–driven discovery of potent, selective, and orally available SARS-CoV-2 PL pro inhibitors, with lead compound PF-07957472 ( 4 ) providing robust efficacy in a mouse-adapted model of COVID-19 infection.
- 30 August 2024
- Published by American Association for the Advancement of Science (AAAS) in Science Advances
- Vol. 10  (35) , eado4288
Top Cited PapersOpen AccessDiscovery of SARS-CoV-2 papain-like protease (PL pro ) inhibitors with efficacy in a murine infection model
Vaccines and first-generation antiviral therapeutics have provided important protection against COVID-19 caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). However, there remains a need for additional therapeutic options that provide enhanced efficacy and protection against potential viral resistance. The SARS-CoV-2 papain-like protease (PL pro ) is one of the two essential cysteine proteases involved in viral replication. While inhibitors of the SARS-CoV-2 main protease have demonstrated clinical efficacy, known PL pro inhibitors have, to date, lacked the inhibitory potency and requisite pharmacokinetics to demonstrate that targeting PL pro translates to in vivo efficacy in a preclinical setting. Here, we report the machine learning–driven discovery of potent, selective, and orally available SARS-CoV-2 PL pro inhibitors, with lead compound PF-07957472 ( 4 ) providing robust efficacy in a mouse-adapted model of COVID-19 infection.
- Open Access
- 26 July 2024
- Published by American Association for the Advancement of Science (AAAS) in Science Advances
- Vol. 10  (30)
In vitro selection and analysis of SARS-CoV-2 nirmatrelvir resistance mutations contributing to clinical virus resistance surveillance
To facilitate the detection and management of potential clinical antiviral resistance, in vitro selection of drug-resistant severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) against the virus M pro inhibitor nirmatrelvir (Paxlovid active component) was conducted. Six M pro mutation patterns containing T304I alone or in combination with T21I, L50F, T135I, S144A, or A173V emerged, with A173V+T304I and T21I+S144A+T304I mutations showing >20-fold resistance each. Biochemical analyses indicated inhibition constant shifts aligned to antiviral results, with S144A and A173V each markedly reducing nirmatrelvir inhibition and M pro activity. SARS-CoV-2 surveillance revealed that in vitro resistance–associated mutations from our studies and those reported in the literature were rarely detected in the Global Initiative on Sharing All Influenza Data database. In the Paxlovid Evaluation of Protease Inhibition for COVID-19 in High-Risk Patients trial, E166V was the only emergent resistance mutation, observed in three Paxlovid-treated patients, none of whom experienced COVID-19–related hospitalization or death.
- 26 July 2024
- Published by American Association for the Advancement of Science (AAAS) in Science Advances
- Vol. 10  (30)
Open AccessIn vitro selection and analysis of SARS-CoV-2 nirmatrelvir resistance mutations contributing to clinical virus resistance surveillance
To facilitate the detection and management of potential clinical antiviral resistance, in vitro selection of drug-resistant severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) against the virus M pro inhibitor nirmatrelvir (Paxlovid active component) was conducted. Six M pro mutation patterns containing T304I alone or in combination with T21I, L50F, T135I, S144A, or A173V emerged, with A173V+T304I and T21I+S144A+T304I mutations showing >20-fold resistance each. Biochemical analyses indicated inhibition constant shifts aligned to antiviral results, with S144A and A173V each markedly reducing nirmatrelvir inhibition and M pro activity. SARS-CoV-2 surveillance revealed that in vitro resistance–associated mutations from our studies and those reported in the literature were rarely detected in the Global Initiative on Sharing All Influenza Data database. In the Paxlovid Evaluation of Protease Inhibition for COVID-19 in High-Risk Patients trial, E166V was the only emergent resistance mutation, observed in three Paxlovid-treated patients, none of whom experienced COVID-19–related hospitalization or death.
- Open Access
- 24 May 2024
- Published by Microbiology Society in Microbial Genomics
- Vol. 10  (5)
Development of a sequence-based in silico OspA typing method for Borrelia burgdorferi sensu lato
Lyme disease (LD), caused by spirochete bacteria of the genus Borrelia burgdorferi sensu lato, remains the most common vectorborne disease in the northern hemisphere. Borrelia outer surface protein A (OspA) is an integral surface protein expressed during the tick cycle, and a validated vaccine target. There are at least 20 recognized Borrelia genospecies, that vary in OspA serotype. This study presents a new in silico sequence- based method for OspA typing using next- generation sequence data. Using a compiled database of over 400 Borrelia genomes encompassing the 4 most common disease- causing genospecies, we characterized OspA diversity in a manner that can accommodate existing and new OspA types and then defined boundaries for classification and assignment of OspA types based on the sequence similarity. To accommodate potential novel OspA types, we have developed a new nomenclature: OspA in silico type (IST). Beyond the ISTs that corresponded to existing OspA serotypes 1-8, we identified nine additional ISTs that cover new OspA variants in B. bavariensis (IST9-10), B. garinii (IST11-12), and other Borrelia genospecies (IST13-17). The IST typing scheme and associated OspA variants are available as part of the PubMLST Borrelia spp. database. Compared to traditional OspA serotyping methods, this new computational pipeline provides a more comprehensive and broadly applicable approach for characterization of OspA type and Borrelia genospecies to support vaccine development.
- 24 May 2024
- Published by Microbiology Society in Microbial Genomics
- Vol. 10  (5)
Open AccessDevelopment of a sequence-based in silico OspA typing method for Borrelia burgdorferi sensu lato
Lyme disease (LD), caused by spirochete bacteria of the genus Borrelia burgdorferi sensu lato, remains the most common vectorborne disease in the northern hemisphere. Borrelia outer surface protein A (OspA) is an integral surface protein expressed during the tick cycle, and a validated vaccine target. There are at least 20 recognized Borrelia genospecies, that vary in OspA serotype. This study presents a new in silico sequence- based method for OspA typing using next- generation sequence data. Using a compiled database of over 400 Borrelia genomes encompassing the 4 most common disease- causing genospecies, we characterized OspA diversity in a manner that can accommodate existing and new OspA types and then defined boundaries for classification and assignment of OspA types based on the sequence similarity. To accommodate potential novel OspA types, we have developed a new nomenclature: OspA in silico type (IST). Beyond the ISTs that corresponded to existing OspA serotypes 1-8, we identified nine additional ISTs that cover new OspA variants in B. bavariensis (IST9-10), B. garinii (IST11-12), and other Borrelia genospecies (IST13-17). The IST typing scheme and associated OspA variants are available as part of the PubMLST Borrelia spp. database. Compared to traditional OspA serotyping methods, this new computational pipeline provides a more comprehensive and broadly applicable approach for characterization of OspA type and Borrelia genospecies to support vaccine development.
- Open Access
Development of a sequence-based in silico OspA typing method for Borrelia burgdorferi sensu lato
Lyme disease (LD), caused by spirochete bacteria of the genus Borrelia burgdorferi sensu lato, remains the most common vector-borne disease in the northern hemisphere. Borrelia outer surface protein A (OspA) is an integral surface protein expressed during the tick cycle, and a validated vaccine target. There are at least 20 recognized Borrelia genospecies, that vary in OspA serotype. Traditional serotyping of Borrelia isolates using OspA-specific monoclonal antibodies is technically challenging and reagent-constrained. This study presents a new in silico sequence-based method for OspA typing using next-generation sequence data. Using a compiled database of over 400 Borrelia genomes encompassing all major genospecies, we characterized OspA diversity in a manner that can accommodate existing and new OspA types and then defined boundaries for classification and assignment of OspA types based on the sequence similarity. To accommodate potential novel OspA types, we have developed a new nomenclature: OspA in silico type (IST). Beyond the ISTs which corresponded to existing OspA serotypes (ST1-8), we identified nine additional ISTs which cover new OspA variants in B. bavariensis (IST9-10), B. garinii (IST11-12), and other Borrelia genospecies (IST13-17). Compared to traditional OspA serotyping methods, this new computational pipeline provides a more comprehensive and broadly applicable approach for characterization of OspA type and Borrelia genospecies to support vaccine development. Impact Statement: As the incidence of LD continues to rise, so does the need to maintain genomic surveillance of disease-causing Borrelia spp. and support clinical development of new vaccines. Towards this goal, introducing the OspA in silico type (IST) nomenclature scheme, as well as the open-source release of this OspA analysis pipeline, will enable characterization of novel Borrelia OspA types using NGS data without the need for traditional, antibody-based serotyping systems.
Open AccessDevelopment of a sequence-based in silico OspA typing method for Borrelia burgdorferi sensu lato
Lyme disease (LD), caused by spirochete bacteria of the genus Borrelia burgdorferi sensu lato, remains the most common vector-borne disease in the northern hemisphere. Borrelia outer surface protein A (OspA) is an integral surface protein expressed during the tick cycle, and a validated vaccine target. There are at least 20 recognized Borrelia genospecies, that vary in OspA serotype. Traditional serotyping of Borrelia isolates using OspA-specific monoclonal antibodies is technically challenging and reagent-constrained. This study presents a new in silico sequence-based method for OspA typing using next-generation sequence data. Using a compiled database of over 400 Borrelia genomes encompassing all major genospecies, we characterized OspA diversity in a manner that can accommodate existing and new OspA types and then defined boundaries for classification and assignment of OspA types based on the sequence similarity. To accommodate potential novel OspA types, we have developed a new nomenclature: OspA in silico type (IST). Beyond the ISTs which corresponded to existing OspA serotypes (ST1-8), we identified nine additional ISTs which cover new OspA variants in B. bavariensis (IST9-10), B. garinii (IST11-12), and other Borrelia genospecies (IST13-17). Compared to traditional OspA serotyping methods, this new computational pipeline provides a more comprehensive and broadly applicable approach for characterization of OspA type and Borrelia genospecies to support vaccine development. Impact Statement: As the incidence of LD continues to rise, so does the need to maintain genomic surveillance of disease-causing Borrelia spp. and support clinical development of new vaccines. Towards this goal, introducing the OspA in silico type (IST) nomenclature scheme, as well as the open-source release of this OspA analysis pipeline, will enable characterization of novel Borrelia OspA types using NGS data without the need for traditional, antibody-based serotyping systems.
- Open Access
- 6 June 2023
- Published by Microbiology Society in Microbial Genomics
- Vol. 9  (6) , 001033
PfaSTer: a machine learning-powered serotype caller for Streptococcus pneumoniae genomes
Streptococcus pneumoniae (pneumococcus) is a leading cause of morbidity and mortality worldwide. Although multi-valent pneumococcal vaccines have curbed the incidence of disease, their introduction has resulted in shifted serotype distributions that must be monitored. Whole genome sequence (WGS) data provide a powerful surveillance tool for tracking isolate serotypes, which can be determined from nucleotide sequence of the capsular polysaccharide biosynthetic operon (cps). Although software exists to predict serotypes from WGS data, most are constrained by requiring high-coverage next-generation sequencing reads. This can present a challenge in respect of accessibility and data sharing. Here we present PfaSTer, a machine learning-based method to identify 65 prevalent serotypes from assembled S. pneumoniae genome sequences. PfaSTer combines dimensionality reduction from k-mer analysis with a Random Forest classifier for rapid serotype prediction. By leveraging the model’s built-in statistical framework, PfaSTer determines confidence in its predictions without the need for coverage-based assessments. We then demonstrate the robustness of this method, returning >97 % concordance when compared to biochemical results and other in silico serotyping tools. PfaSTer is open source and available at: https://github.com/pfizer-opensource/pfaster.
- 6 June 2023
- Published by Microbiology Society in Microbial Genomics
- Vol. 9  (6) , 001033
Open AccessPfaSTer: a machine learning-powered serotype caller for Streptococcus pneumoniae genomes
Streptococcus pneumoniae (pneumococcus) is a leading cause of morbidity and mortality worldwide. Although multi-valent pneumococcal vaccines have curbed the incidence of disease, their introduction has resulted in shifted serotype distributions that must be monitored. Whole genome sequence (WGS) data provide a powerful surveillance tool for tracking isolate serotypes, which can be determined from nucleotide sequence of the capsular polysaccharide biosynthetic operon (cps). Although software exists to predict serotypes from WGS data, most are constrained by requiring high-coverage next-generation sequencing reads. This can present a challenge in respect of accessibility and data sharing. Here we present PfaSTer, a machine learning-based method to identify 65 prevalent serotypes from assembled S. pneumoniae genome sequences. PfaSTer combines dimensionality reduction from k-mer analysis with a Random Forest classifier for rapid serotype prediction. By leveraging the model’s built-in statistical framework, PfaSTer determines confidence in its predictions without the need for coverage-based assessments. We then demonstrate the robustness of this method, returning >97 % concordance when compared to biochemical results and other in silico serotyping tools. PfaSTer is open source and available at: https://github.com/pfizer-opensource/pfaster.
- Open Access
PfaSTer: A ML-powered serotype caller for Streptococcus pneumoniae genomes
Streptococcus pneumoniae (pneumococcus) is a leading cause of morbidity and mortality worldwide. Although multi-valent pneumococcal vaccines have curbed the incidence of disease, their introduction has resulted in shifted serotype distributions that must be monitored. Whole genome sequence (WGS) data provides a powerful surveillance tool for tracking isolate serotypes, which can be determined from nucleotide sequence of the capsular polysaccharide biosynthetic operon ( cps ). Although software exists to predict serotypes from WGS data, their use is constrained by the requirement of high-coverage Next Generation Sequencing (NGS) reads. This can present a challenge in so far as accessibility and data sharing. Here we present PfaSTer, a method to identify 65 prevalent serotypes from individual S. pneumoniae genome sequences rather than primary NGS data. PfaSTer combines dimensionality reduction from k-mer analysis with machine learning, allowing for rapid serotype prediction without the need for coverage-based assessments. We then demonstrate the robustness of this method, returning >97% concordance when compared to biochemical results and other in-silico serotypers. PfaSTer is open source and available at: https://github.com/pfizer-opensource/pfaster .
Open AccessPfaSTer: A ML-powered serotype caller for Streptococcus pneumoniae genomes
Streptococcus pneumoniae (pneumococcus) is a leading cause of morbidity and mortality worldwide. Although multi-valent pneumococcal vaccines have curbed the incidence of disease, their introduction has resulted in shifted serotype distributions that must be monitored. Whole genome sequence (WGS) data provides a powerful surveillance tool for tracking isolate serotypes, which can be determined from nucleotide sequence of the capsular polysaccharide biosynthetic operon ( cps ). Although software exists to predict serotypes from WGS data, their use is constrained by the requirement of high-coverage Next Generation Sequencing (NGS) reads. This can present a challenge in so far as accessibility and data sharing. Here we present PfaSTer, a method to identify 65 prevalent serotypes from individual S. pneumoniae genome sequences rather than primary NGS data. PfaSTer combines dimensionality reduction from k-mer analysis with machine learning, allowing for rapid serotype prediction without the need for coverage-based assessments. We then demonstrate the robustness of this method, returning >97% concordance when compared to biochemical results and other in-silico serotypers. PfaSTer is open source and available at: https://github.com/pfizer-opensource/pfaster .
- Open Access
- 30 August 2022
- Published by American Society for Microbiology in mBio
- Vol. 13  (4) , e0086922
Genetic Surveillance of SARS-CoV-2 M pro Reveals High Sequence and Structural Conservation Prior to the Introduction of Protease Inhibitor Paxlovid
The recent authorization of oral severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) antivirals, such as Paxlovid, has ushered in a new era of the COVID-19 pandemic. The emergence of new variants, as well as the selective pressure imposed by antiviral drugs themselves, raises concern for potential escape mutations in key drug binding motifs.
- 30 August 2022
- Published by American Society for Microbiology in mBio
- Vol. 13  (4) , e0086922
Open AccessGenetic Surveillance of SARS-CoV-2 M pro Reveals High Sequence and Structural Conservation Prior to the Introduction of Protease Inhibitor Paxlovid
The recent authorization of oral severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) antivirals, such as Paxlovid, has ushered in a new era of the COVID-19 pandemic. The emergence of new variants, as well as the selective pressure imposed by antiviral drugs themselves, raises concern for potential escape mutations in key drug binding motifs.